申请人:Hoffmann-La Roche Inc.
公开号:US20130150407A1
公开(公告)日:2013-06-13
The invention is concerned with the compounds of formula (I):
and pharmaceutically acceptable salts thereof, wherein R
1
, R
2
, R
3
and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
这项发明涉及式(I)的化合物:
及其药学上可接受的盐,其中R
1
,R
2
,R
3
和X在详细说明和权利要求中有定义。此外,本发明涉及制造和使用式I的化合物的方法,以及含有这种化合物的药物组合物。式I的化合物是CRTH2受体的拮抗剂或部分激动剂,可能在治疗与该受体相关的疾病和紊乱方面有用,如哮喘。